Legendre Christophe, Brault Yves, Morales José M, Oberbauer Rainer, Altieri Paolo, Riad Hany, Mahony John, Messina Maria, Pussell Bruce, Martínez Javier G, Lelong Magali, Burke James T, Neylan John F
Hôpital Necker, Paris, France.
Clin Transplant. 2007 May-Jun;21(3):330-6. doi: 10.1111/j.1399-0012.2007.00645.x.
Changes in calculated glomerular filtration rate (GFR) from baseline to five yr were analyzed in relation to risk factors among renal transplant recipients. At three months after transplantation (baseline), 430 eligible patients receiving sirolimus (SRL), cyclosporine (CsA), and steroids (ST) were randomly assigned (1:1) to continue SRL-CsA-ST or have CsA withdrawn and SRL trough levels increased (SRL-ST group). For each risk factor, changes from baseline were compared within each treatment using a t-test and between treatments using ANCOVA. Univariate then multivariate robust linear regression analyses were also performed. In the SRL-ST group, changes from baseline were not significantly different for any risk factor. With the exception of cold ischemia time >24 h, GFR values declined significantly for all risk factors in SRL-CsA-ST patients. For all risk factors, except second transplant or cold ischemia time >24 h, renal function was significantly different between groups. By order of significance in the multivariate analysis, treatment (p < 0.001), donor age (p < 0.001), proteinuria (p < 0.001), and biopsy-confirmed rejection (p = 0.010) were significant predictors of GFR change from baseline. In conclusion, patients with risk factors for reduced renal function benefit from SRL maintenance therapy without CsA vs. those remaining on CsA.
分析了肾移植受者从基线到五年的计算肾小球滤过率(GFR)变化与风险因素的关系。在移植后三个月(基线),430名符合条件的接受西罗莫司(SRL)、环孢素(CsA)和类固醇(ST)治疗的患者被随机分配(1:1)继续接受SRL-CsA-ST治疗或停用CsA并提高SRL谷浓度(SRL-ST组)。对于每个风险因素,使用t检验在每种治疗方法内比较基线变化,并使用协方差分析比较不同治疗方法之间的变化。还进行了单变量和多变量稳健线性回归分析。在SRL-ST组中,任何风险因素的基线变化均无显著差异。除冷缺血时间>24小时外,SRL-CsA-ST患者所有风险因素的GFR值均显著下降。对于所有风险因素,除二次移植或冷缺血时间>24小时外,两组之间的肾功能存在显著差异。按多变量分析中的显著性顺序,治疗(p<0.001)、供体年龄(p<0.001)、蛋白尿(p<0.001)和活检证实的排斥反应(p = 0.010)是GFR从基线变化的显著预测因素。总之,与继续使用CsA的患者相比,存在肾功能降低风险因素的患者从无CsA的SRL维持治疗中获益。